.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The landmark 5-year follow-up data from the DiRECT trial provides clear evidence regarding diabetes remission cost-effectiveness. Recent results show that an intensive weight management program significantly improves long-term health outcomes while reducing overall healthcare costs. Consequently, this intervention offers a sustainable solution for managing Type 2 Diabetes (T2DM) in primary care settings.
Over the five-year period, participants in the intervention arm achieved an average weight loss of 6.1 kg. Furthermore, approximately 10% of these individuals remained in remission from T2DM at the five-year mark. Notably, the total discounted healthcare cost savings per participant amounted to £2,091, excluding the initial intervention costs. Therefore, the program demonstrates both clinical efficacy and financial viability.
The researchers calculated an Incremental Cost-Effectiveness Ratio (ICER) of £13,541 per Quality-Adjusted Life-Year (QALY). This figure falls well below the standard willingness-to-pay thresholds used in many global healthcare systems. Moreover, the probability of the intervention being cost-effective reaches 98% at a £20,000 per QALY threshold. In contrast to standard care, this approach provides more life-years in remission and a better quality of life for patients.
Healthcare providers should consider total diet replacement and structured support as a primary strategy for early T2DM. This model reduces the medication burden, specifically for anti-hypertensive and anti-diabetic drugs. Additionally, the long-term reduction in primary and secondary care contacts offsets the initial costs of the formula diet and practitioner visits. Ultimately, prioritizing weight-mediated remission can transform the economic landscape of diabetes care.
The intervention uses the Counterweight-Plus program, which includes a low-energy formula diet (825–853 kcal/day) for 12–20 weeks, followed by food reintroduction and long-term weight maintenance support.
Yes, the DiRECT trial showed that 10% of participants remained in remission at 5 years, with those maintaining significant weight loss having the highest success rates.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Davies A et al. Cost-effectiveness of the diabetes remission clinical trial (DiRECT)/Counterweight-Plus weight management programme, based on 5-year follow-up. Diabet Med. 2026 Mar 29. doi: 10.1111/dme.70306. PMID: 41904649.
Lean MEJ, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12(4):233-246.
Arpan, Singh N, et al. Achieving Diabetes Remission: Current Guidelines and Emerging Pharmacotherapies in India. J Assoc Physicians India 2025;73(10):83-86.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The 5-year DiRECT trial results prove that intensive weight management for T2DM remission is highly cost-effective, saving £2,091 in healthcare costs per pa...
5 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
